M&As this week: Miroculus, Sinocare, DexCom, Stryker Corporation

5 May 2016 (Last Updated May 5th, 2016 18:30)

Miroculus, a developer of microRNA-based diagnostic platforms, has entered an agreement to acquire Kapplex, a developer of multiplexed point-of-care diagnostic platforms based in Toronto, to advance diagnostics for complex diseases.

Miroculus-Kapplex device prototype

Miroculus, a developer of microRNA-based diagnostic platforms, has entered an agreement to acquire Kapplex, a developer of multiplexed point-of-care diagnostic platforms based in Toronto, to advance diagnostics for complex diseases.

Following the acquisition, Digital Microfluidic (DMF), the proprietary platform of Kapplex, will be combined with Miroculus' technology to form a single product called the Miroculus-Kapplex technology, which will detect complex conditions, such as cancer or infectious diseases, in a less invasive way.

Kapplex will become a Canadian subsidiary of Miroculus upon completion of the transaction.

Sinocare, a blood glucose monitoring systems provider based in China, has signed an agreement to acquire PTS Diagnostics, a point-of-care diagnostics solutions provider based in Indiana, US, to provide more innovative and systematic solutions to fight chronic diseases such as diabetes.

According to the terms of the agreement, the Chinese medical device provider will own an 100% stake in PTS Diagnostics for up to $200m cash consideration including a contingent payment of up to $90m for the successful completion of certain milestones.

The acquisition will enable both companies to expand their global reach and to provide integrated solutions such as medical devices and information management systems that will help improve diagnosis and monitoring of multiple chronic diseases.

Evercore Partners is the exclusive financial advisor to Sinocare, while J.P. Morgan Securities is the advisor for PTS Diagnostics on the transaction, which is scheduled for completion within 120 days, subject to certain conditions.

DexCom, a medical technology firm based in San Diego, US, has announced the acquisition of its distribution partner, Nintamed, a medical technology company specialising in diabetes monitoring products with operations in Germany, Austria, and Switzerland.

The acquisition will allow Dexcom to improve international access to its continuous glucose monitoring (CGM) systems.
Nintamed, which has been Dexcom's exclusive distributor from the past six years, will now work closely with the company's new international headquarters in Edinburgh, Scotland.

Stryker Corporation, a leading medical technology company, has completed the acquisition of Stanmore Implants Worldwide Limited, an orthopaedic oncology firm based in the UK, for £35.6m ($51.85m).

Through the acquisition, Stryker gains access to Stanmore's differentiated technologies to treat adult and juvenile orthopaedic tumours and develop effective solutions for surgeons in that field.

Global healthcare company Abbott Laboratories (ABT), specialising in developing medical products and technologies, has announced a definitive agreement with St. Jude Medical, a medical device company specialising in cardiovascular medical technologies.

Under the terms of the agreement, ABT will acquire St. Jude Medical for $25bn. The acquisition will create a premier medical device business with a powerful pipeline ready to deliver next-generation medical devices across cardiovascular, diabetes, vision and neuro-modulation patient care.

It will also enhance ABT's strategic and competitive position in the global markets.


Image: Miroculus-Kapplex device. Photo: courtesy of GlobeNewswire.